3.26
+0.05(+1.56%)
Currency In USD
Address
100 Summer Street
Boston, MA 02110
United States of America
Phone
617 621 7722
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
253
First IPO Date
February 03, 2010
| Name | Title | Pay | Year Born |
| Thomas A. McCourt | Chief Executive Officer & Director | 1.36M | 1957 |
| John Minardo | Senior VP, Chief Legal Officer & Secretary | 717,470 | 1976 |
| Michael Shetzline | Chief Medical Officer, Senior Vice President and Head of Research & Drug Development | 756,701 | 1959 |
| Rosario Lobrutto | VP & Global Head of Technical Operations | 0 | N/A |
| Greg Martini | Senior VP, CFO & Investor Relations | 0 | 1989 |
| Jeff Ruberti | Chief Strategy Officer | 0 | N/A |
| Ronald Silver | Senior Vice President, Corporate Controller & Principal Accounting Officer | 0 | 1982 |
| Tammi Gaskins | Senior Vice President & Chief Commercial Officer. | 0 | 1973 |
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.